Purchase this article with an account.
J.-Y. Hyon, Y. Lee, P.-Y. Yun; Clinical Efficacy of Antiinflammatory Treatment in Sjögren’s Syndrome. Invest. Ophthalmol. Vis. Sci. 2007;48(13):356.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluated the clinical efficacy of anti-inflammatory therapy in the management of primary Sjögren’s syndrome.
Thirty eight patients with primary Sjögren’s syndrome were studied. Diagnosis of Sjögren’s syndrome was made based on the classification criteria by American-European Consensus Group. Fluorescein staining scores, rose bengal staining scores, Schirmer test scores, tear film break up time, and functional parameters include ocular surface disease index (OSDI), and visual analog scale (VAS) were measured at first visit. Anti-inflammatory therapy included topical corticosteroid, topical autologous serum, and topical cyclosporin A. The clinical efficacy of anti-inflammatory treatment was evaluated with subjective symptoms and objective signs including Schirmer-1 test, break up time, rose bengal score, and fluorescein score.
Patients with Sjögren’s syndrome had higher rose bengal score than non-Sjögren’s dry eye patients (p<0.05). OSDI showed better correlation with fluorescein score than VAS. Subjective symptoms improved with anti-inflammatory treatment in 70% of patients with primary Sjögren’s syndrome. Anti-inflammatory treatment provided significant improvement in visual acuity and fluorescein score, but did not affect Schirmer values, tear break up time, and rose bengal score.
Anti-inflammatory therapy in primary Sjögren’s syndrome significantly improved subjective symptoms as well as objective ocular signs. but we could not find the evidence that the anti-inflammatory treatment increases tear production in Sjögren’s syndrome in this study.
This PDF is available to Subscribers Only